{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T19:57:24Z","timestamp":1793908644141,"version":"4.8.0"},"reference-count":74,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,3]],"date-time":"2024-06-03T00:00:00Z","timestamp":1717372800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100013342","name":"National Institute for Health Research Imperial Biomedical Research Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013342","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"UKRI Medical Research Council","doi-asserted-by":"publisher","award":["MC-A654-5QB10"],"award-info":[{"award-number":["MC-A654-5QB10"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"UKRI Medical Research Council","doi-asserted-by":"publisher","award":["MR\/P002536\/1"],"award-info":[{"award-number":["MR\/P002536\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010663","name":"ERC","doi-asserted-by":"publisher","award":["715662"],"award-info":[{"award-number":["715662"]}],"id":[{"id":"10.13039\/100010663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000781","name":"European Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000781","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014653","name":"Manchester Biomedical Research Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014653","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100023262","name":"The Jon Moulton Charity Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100023262","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001648","name":"European Foundation for the Study of Diabetes","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001648","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.biopha.2024.116888","type":"journal-article","created":{"date-parts":[[2024,6,10]],"date-time":"2024-06-10T19:14:01Z","timestamp":1718046841000},"page":"116888","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Chronic treatment with glucagon-like peptide-1 and glucagon receptor co-agonist causes weight loss-independent improvements in hepatic steatosis in mice with diet-induced obesity"],"prefix":"10.1016","volume":"176","author":[{"given":"Emma Rose","family":"McGlone","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David C.D.","family":"Hope","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iona","family":"Davies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marian","family":"Dore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rob","family":"Goldin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhigang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia V.","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panagiotis A.","family":"Vorkas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"Khoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2316-1830","authenticated-orcid":false,"given":"David","family":"Carling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Minnion","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen R.","family":"Bloom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tricia M-M.","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.biopha.2024.116888_bib1","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.biopha.2024.116888_bib2","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.cgh.2020.05.064","article-title":"Nonalcoholic steatohepatitis is the most rapidly increasing indication for liver transplantation in the United States","volume":"19","author":"Younossi","year":"2021","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"2","key":"10.1016\/j.biopha.2024.116888_bib3","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1053\/j.gastro.2015.04.005","article-title":"Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis","volume":"149","author":"Vilar-Gomez","year":"2015","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.biopha.2024.116888_bib4","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/hep.23276","article-title":"Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis","volume":"51","author":"Promrat","year":"2010","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.biopha.2024.116888_bib5","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.soard.2018.12.002","article-title":"Bariatric surgery improves nonalcoholic fatty liver disease: a contemporary systematic review and meta-analysis","volume":"15","author":"Fakhry","year":"2019","journal-title":"Surg. Obes. Relat. Dis."},{"key":"10.1016\/j.biopha.2024.116888_bib6","doi-asserted-by":"crossref","first-page":"m4747","DOI":"10.1136\/bmj.m4747","article-title":"Management of non-alcoholic fatty liver disease","volume":"372","author":"Petroni","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.biopha.2024.116888_bib7","doi-asserted-by":"crossref","unstructured":"Harrison et al., New Engl J Med 2024; 390: 497-509, DOI:10.1056\/NEJMoa2309000.","DOI":"10.1056\/NEJMoa2309000"},{"issue":"7","key":"10.1016\/j.biopha.2024.116888_bib8","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1038\/s41574-018-0016-2","article-title":"Glucagon-like peptide 1 in health and disease","volume":"14","author":"Andersen","year":"2018","journal-title":"Nat. Rev. Endocrinol."},{"issue":"10019","key":"10.1016\/j.biopha.2024.116888_bib9","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S0140-6736(15)00803-X","article-title":"Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study","volume":"387","author":"Armstrong","year":"2016","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.biopha.2024.116888_bib10","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","article-title":"A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis","volume":"384","author":"Newsome","year":"2021","journal-title":"N. Engl. J. Med"},{"issue":"8","key":"10.1016\/j.biopha.2024.116888_bib11","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1111\/dom.13212","article-title":"Running on mixed fuel-dual agonistic approach of GLP-1 and GCG receptors leads to beneficial impact on body weight and blood glucose control: a comparative study between mice and non-human primates","volume":"20","author":"Elvert","year":"2018","journal-title":"Diabetes Obes. Metab."},{"issue":"12","key":"10.1016\/j.biopha.2024.116888_bib12","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1111\/dom.12735","article-title":"Robust anti-obesity and metabolic effects of a dual GLP-1\/glucagon receptor peptide agonist in rodents and non-human primates","volume":"18","author":"Henderson","year":"2016","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.biopha.2024.116888_bib13","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.peptides.2018.04.008","article-title":"Oxyntomodulin analogue increases energy expenditure via the glucagon receptor","volume":"104","author":"Scott","year":"2018","journal-title":"Peptides"},{"key":"10.1016\/j.biopha.2024.116888_bib14","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.peptides.2017.09.018","article-title":"Oxyntomodulin: actions and role in diabetes","volume":"100","author":"Holst","year":"2018","journal-title":"Peptides"},{"issue":"10","key":"10.1016\/j.biopha.2024.116888_bib15","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.2337\/db09-0278","article-title":"Glucagon-like peptide 1\/glucagon receptor dual agonism reverses obesity in mice","volume":"58","author":"Pocai","year":"2009","journal-title":"Diabetes"},{"issue":"6","key":"10.1016\/j.biopha.2024.116888_bib16","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1139\/cjpp-2017-0683","article-title":"Coagonist of glucagon-like peptide-1 and glucagon receptors ameliorates nonalcoholic fatty liver disease","volume":"96","author":"Patel","year":"2018","journal-title":"Can. J. Physiol. Pharm."},{"issue":"5","key":"10.1016\/j.biopha.2024.116888_bib17","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/s42255-020-0209-6","article-title":"Resolution of NASH and hepatic fibrosis by the GLP-1R\/GcgR dual-agonist Cotadutide via modulating mitochondrial function and lipogenesis","volume":"2","author":"Boland","year":"2020","journal-title":"Nat. Metab."},{"issue":"5","key":"10.1016\/j.biopha.2024.116888_bib18","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.cmet.2008.09.008","article-title":"The glucagon receptor is required for the adaptive metabolic response to fasting","volume":"8","author":"Longuet","year":"2008","journal-title":"Cell Metab."},{"key":"10.1016\/j.biopha.2024.116888_bib19","article-title":"Glucagon regulates hepatic lipid metabolism via cAMP and Insig-2 signaling: implication for the pathogenesis of hypertriglyceridemia and hepatic steatosis","volume":"6","author":"Wang","year":"2016","journal-title":"Sci. Rep."},{"issue":"3-4","key":"10.1016\/j.biopha.2024.116888_bib20","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.anireprosci.2006.11.003","article-title":"Exogenous glucagon effects on health and reproductive performance of lactating dairy cows with mild fatty liver","volume":"102","author":"Bobe","year":"2007","journal-title":"Anim. Reprod. Sci."},{"issue":"11","key":"10.1016\/j.biopha.2024.116888_bib21","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1111\/dom.12958","article-title":"Treatment with LY2409021, a glucagon receptor antagonist, increases liver fat in patients with type 2 diabetes","volume":"19","author":"Guzman","year":"2017","journal-title":"Diabetes Obes. Metab."},{"issue":"3","key":"10.1016\/j.biopha.2024.116888_bib22","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1002\/hep.28962","article-title":"A novel glucagon-like peptide 1\/glucagon receptor dual agonist improves steatohepatitis and liver regeneration in mice","volume":"65","author":"Valdecantos","year":"2017","journal-title":"Hepatology"},{"issue":"10","key":"10.1016\/j.biopha.2024.116888_bib23","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/nchembio.209","article-title":"A new glucagon and GLP-1 co-agonist eliminates obesity in rodents","volume":"5","author":"Day","year":"2009","journal-title":"Nat. Chem. Biol."},{"issue":"2","key":"10.1016\/j.biopha.2024.116888_bib24","doi-asserted-by":"crossref","first-page":"E261","DOI":"10.1152\/ajpendo.00676.2007","article-title":"Comparison between surrogate indexes of insulin sensitivity and resistance and hyperinsulinemic euglycemic clamp estimates in mice","volume":"294","author":"Lee","year":"2008","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"issue":"13","key":"10.1016\/j.biopha.2024.116888_bib25","doi-asserted-by":"crossref","first-page":"3043","DOI":"10.1016\/j.celrep.2017.03.011","article-title":"Liver-Specific Activation of AMPK Prevents Steatosis on a High-Fructose Diet","volume":"18","author":"Woods","year":"2017","journal-title":"Cell Rep."},{"issue":"6","key":"10.1016\/j.biopha.2024.116888_bib26","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/hep.20701","article-title":"Design and validation of a histological scoring system for nonalcoholic fatty liver disease","volume":"41","author":"Kleiner","year":"2005","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.biopha.2024.116888_bib27","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1210\/en.2008-0828","article-title":"Investigation of structure-activity relationships of Oxyntomodulin (Oxm) using Oxm analogs","volume":"150","author":"Druce","year":"2009","journal-title":"Endocrinology"},{"issue":"9","key":"10.1016\/j.biopha.2024.116888_bib28","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1111\/liv.15614","article-title":"Sleeve gastrectomy causes weight-loss independent improvements in hepatic steatosis","volume":"43","author":"McGlone","year":"2023","journal-title":"Liver Int."},{"issue":"3","key":"10.1016\/j.biopha.2024.116888_bib29","doi-asserted-by":"crossref","DOI":"10.1530\/JOE-23-0365","article-title":"Glucagon resistance and metabolic-associated steatotic liver disease: a review of the evidence","volume":"261","author":"McGlone","year":"2024","journal-title":"J. Endocrinol."},{"issue":"1","key":"10.1016\/j.biopha.2024.116888_bib30","doi-asserted-by":"crossref","first-page":"7501","DOI":"10.1038\/s41598-019-43928-7","article-title":"The differential expression of cide family members is associated with nafld progression from steatosis to steatohepatitis","volume":"9","author":"Sans","year":"2019","journal-title":"Sci. Rep."},{"issue":"2","key":"10.1016\/j.biopha.2024.116888_bib31","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/nrm2335","article-title":"Lipid signalling in disease","volume":"9","author":"Wymann","year":"2008","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"25","key":"10.1016\/j.biopha.2024.116888_bib32","doi-asserted-by":"crossref","first-page":"2661","DOI":"10.3748\/wjg.v24.i25.2661","article-title":"Apoptosis and non-alcoholic fatty liver diseases","volume":"24","author":"Kanda","year":"2018","journal-title":"World J. Gastroenterol."},{"issue":"1","key":"10.1016\/j.biopha.2024.116888_bib33","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1002\/hep.27036","article-title":"Aldehyde dehydrogenase 2 deficiency ameliorates alcoholic fatty liver but worsens liver inflammation and fibrosis in mice","volume":"60","author":"Kwon","year":"2014","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.biopha.2024.116888_bib34","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1124\/dmd.117.077636","article-title":"Effect of flavin-containing monooxygenase genotype, mouse strain, and gender on trimethylamine N-oxide production, plasma cholesterol concentration, and an index of atherosclerosis","volume":"46","author":"Veeravalli","year":"2018","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.biopha.2024.116888_bib35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bbrc.2022.01.060","article-title":"Changes of flavin-containing monooxygenases and trimethylamine-N-oxide may be involved in the promotion of non-alcoholic fatty liver disease by intestinal microbiota metabolite trimethylamine","volume":"594","author":"Shi","year":"2022","journal-title":"Biochem Biophys. Res Commun."},{"key":"10.1016\/j.biopha.2024.116888_bib36","unstructured":"Shulman, G.I., Petersen, K.F., 2017. Metabolism. In: Boron, W.F.M.D.P., Boulpaep, E.L.M.D., editors. Medical Physiology, p. 1170-1192.e1171."},{"key":"10.1016\/j.biopha.2024.116888_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2022.115250","article-title":"Emerging role of carboxylesterases in nonalcoholic fatty liver disease","volume":"205","author":"Liu","year":"2022","journal-title":"Biochem. Pharm."},{"issue":"40","key":"10.1016\/j.biopha.2024.116888_bib38","doi-asserted-by":"crossref","first-page":"E9499","DOI":"10.1073\/pnas.1806635115","article-title":"ACSS2 promotes systemic fat storage and utilization through selective regulation of genes involved in lipid metabolism","volume":"115","author":"Huang","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"12","key":"10.1016\/j.biopha.2024.116888_bib39","doi-asserted-by":"crossref","first-page":"3438","DOI":"10.1111\/jgh.15627","article-title":"Insulin-like growth factor binding protein 1 ameliorates lipid accumulation and inflammation in nonalcoholic fatty liver disease","volume":"36","author":"Pan","year":"2021","journal-title":"J. Gastroenterol. Hepatol."},{"issue":"5","key":"10.1016\/j.biopha.2024.116888_bib40","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1002\/bip.22072","article-title":"Optimization of co-agonism at GLP-1 and glucagon receptors to safely maximize weight reduction in DIO-rodents","volume":"98","author":"Day","year":"2012","journal-title":"Biopolymers"},{"issue":"1","key":"10.1016\/j.biopha.2024.116888_bib41","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-01912-0","article-title":"A glucagon analogue decreases body weight in mice via signalling in the liver","volume":"11","author":"Hinds","year":"2021","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.biopha.2024.116888_bib42","first-page":"72","article-title":"Glucagon increases energy expenditure independently of brown adipose tissue activation in humans","volume":"18","author":"Salem","year":"2016","journal-title":"Diabetes\u00a0Obes. Metab."},{"key":"10.1016\/j.biopha.2024.116888_bib43","doi-asserted-by":"crossref","first-page":"413","DOI":"10.3389\/fphys.2019.00413","article-title":"Glucagon receptor signaling and lipid metabolism","volume":"10","author":"Galsgaard","year":"2019","journal-title":"Front Physiol."},{"issue":"1","key":"10.1016\/j.biopha.2024.116888_bib44","doi-asserted-by":"crossref","first-page":"6666","DOI":"10.1038\/s41598-022-10577-2","article-title":"Effects of ALT-801, a GLP-1 and glucagon receptor dual agonist, in a translational mouse model of non-alcoholic steatohepatitis","volume":"12","author":"Nestor","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biopha.2024.116888_bib45","unstructured":"Boehringer Ingelheim, Survodutide Phase II trial shows 83% of adults treated achieved groundbreaking results in liver disease due to MASH, with significant improvements in fibrosis, 2024. Available at https:\/\/www.boehringer-ingelheim.com\/human-health\/metabolic-diseases\/survodutide-top-line-results-mash-fibrosis. (Accessed 1 May 2024)."},{"issue":"4","key":"10.1016\/j.biopha.2024.116888_bib46","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/j.jhep.2023.05.013","article-title":"A phase IIa active-comparator-controlled study to evaluate the efficacy and safety of efinopegdutide in patients with non-alcoholic fatty liver disease","volume":"79","author":"Romero-G\u00f3mez","year":"2023","journal-title":"J. Hepatol."},{"key":"10.1016\/j.biopha.2024.116888_bib47","unstructured":"American Diabetes Association, ADA Meeting News, 2023. \u3008https:\/\/www.adameetingnews.org\/live-updates\/session-coverage\/phase-2-trial-results-demonstrate-benefits-of-retatrutide-in-obesity-type-2-diabetes-nash\/\u3009. (Accessed 22 December 2023)."},{"issue":"6","key":"10.1016\/j.biopha.2024.116888_bib48","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1053\/j.gastro.2006.02.024","article-title":"The evolution of severe steatosis after bariatric surgery is related to insulin resistance","volume":"130","author":"Mathurin","year":"2006","journal-title":"Gastroenterology"},{"issue":"9","key":"10.1016\/j.biopha.2024.116888_bib49","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1111\/hepr.12634","article-title":"Liraglutide ameliorates non-alcoholic fatty liver disease by enhancing mitochondrial architecture and promoting autophagy through the SIRT1\/SIRT3-FOXO3a pathway","volume":"46","author":"Tong","year":"2016","journal-title":"Hepatol. Res."},{"issue":"9","key":"10.1016\/j.biopha.2024.116888_bib50","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0025269","article-title":"GLP-1 analogs reduce hepatocyte steatosis and improve survival by enhancing the unfolded protein response and promoting macroautophagy","volume":"6","author":"Sharma","year":"2011","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.biopha.2024.116888_bib51","doi-asserted-by":"crossref","first-page":"179","DOI":"10.3748\/wjg.v24.i2.179","article-title":"Metabolic and hepatic effects of liraglutide, obeticholic acid and elafibranor in diet-induced obese mouse models of biopsy-confirmed nonalcoholic steatohepatitis","volume":"24","author":"Tolbol","year":"2018","journal-title":"World J. Gastroenterol."},{"issue":"4","key":"10.1016\/j.biopha.2024.116888_bib52","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.bbrc.2016.05.086","article-title":"GLP-1 analogue improves hepatic lipid accumulation by inducing autophagy via AMPK\/mTOR pathway","volume":"476","author":"He","year":"2016","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"2","key":"10.1016\/j.biopha.2024.116888_bib53","doi-asserted-by":"crossref","first-page":"G225","DOI":"10.1152\/ajpgi.00274.2011","article-title":"Glp-1 analog, liraglutide, ameliorates hepatic steatosis and cardiac hypertrophy in C57BL\/6J mice fed a Western diet","volume":"302","author":"Mells","year":"2012","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"issue":"1","key":"10.1016\/j.biopha.2024.116888_bib54","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1530\/JOE-16-0478","article-title":"The effects of liraglutide in mice with diet-induced obesity studied by metabolomics","volume":"233","author":"Buganova","year":"2017","journal-title":"J. Endocrinol."},{"issue":"2","key":"10.1016\/j.biopha.2024.116888_bib55","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.jhep.2015.08.038","article-title":"Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis","volume":"64","author":"Armstrong","year":"2016","journal-title":"J. Hepatol."},{"issue":"9","key":"10.1016\/j.biopha.2024.116888_bib56","doi-asserted-by":"crossref","first-page":"3288","DOI":"10.1210\/en.2013-2157","article-title":"Liraglutide enhances insulin sensitivity by activating AMP-activated protein kinase in male Wistar rats","volume":"155","author":"Yamazaki","year":"2014","journal-title":"Endocrinology"},{"issue":"9","key":"10.1016\/j.biopha.2024.116888_bib57","doi-asserted-by":"crossref","first-page":"3473","DOI":"10.1210\/en.2014-1052","article-title":"Long term exendin-4 treatment reduces food intake and body weight and alters expression of brain homeostatic and reward markers","volume":"155","author":"Yang","year":"2014","journal-title":"Endocrinology"},{"issue":"4","key":"10.1016\/j.biopha.2024.116888_bib58","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.2337\/db12-0797","article-title":"Coadministration of glucagon-like peptide-1 during glucagon infusion in humans results in increased energy expenditure and amelioration of hyperglycemia","volume":"62","author":"Tan","year":"2013","journal-title":"Diabetes"},{"issue":"24","key":"10.1016\/j.biopha.2024.116888_bib59","doi-asserted-by":"crossref","first-page":"6515","DOI":"10.1128\/MCB.00489-09","article-title":"Identification of a novel amino acid response pathway triggering ATF2 phosphorylation in mammals","volume":"29","author":"Chaveroux","year":"2009","journal-title":"Mol. Cell Biol."},{"issue":"9","key":"10.1016\/j.biopha.2024.116888_bib60","doi-asserted-by":"crossref","first-page":"3263","DOI":"10.1172\/JCI85946","article-title":"A liver stress-endocrine nexus promotes metabolic integrity during dietary protein dilution","volume":"126","author":"Maida","year":"2016","journal-title":"J. Clin. Invest"},{"issue":"9","key":"10.1016\/j.biopha.2024.116888_bib61","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.2337\/db17-1502","article-title":"Glucagon receptor signaling regulates energy metabolism via hepatic farnesoid X receptor and fibroblast growth factor 21","volume":"67","author":"Kim","year":"2018","journal-title":"Diabetes"},{"issue":"1","key":"10.1016\/j.biopha.2024.116888_bib62","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1210\/endocr\/bqz013","article-title":"Glucagon-receptor signaling reverses hepatic steatosis independent of leptin receptor expression","volume":"161","author":"Nason","year":"2020","journal-title":"Endocrinology"},{"issue":"24","key":"10.1016\/j.biopha.2024.116888_bib63","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21249368","article-title":"Unraveling the role of leptin in liver function and its relationship with liver diseases","volume":"21","author":"Martinez-Una","year":"2020","journal-title":"Int J. Mol. Sci."},{"key":"10.1016\/j.biopha.2024.116888_bib64","article-title":"The role of FGF21 and its analogs on liver associated diseases","volume":"9","author":"Falamarzi","year":"2022","journal-title":"Front. Med. (Lausanne)"},{"issue":"11","key":"10.1016\/j.biopha.2024.116888_bib65","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2022.105296","article-title":"Opposing effects of chronic glucagon receptor agonism and antagonism on amino acids, hepatic gene expression, and alpha cells","volume":"25","author":"Elmelund","year":"2022","journal-title":"iScience"},{"issue":"5","key":"10.1016\/j.biopha.2024.116888_bib66","doi-asserted-by":"crossref","DOI":"10.3390\/metabo12050411","article-title":"Renin-angiotensin system in liver metabolism: gender differences and role of incretins","volume":"12","author":"Mastoor","year":"2022","journal-title":"Metabolites"},{"issue":"9","key":"10.1016\/j.biopha.2024.116888_bib67","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1016\/j.cmet.2022.07.013","article-title":"LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept","volume":"34","author":"Coskun","year":"2022","journal-title":"Cell Metab."},{"issue":"4","key":"10.1016\/j.biopha.2024.116888_bib68","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1111\/dom.14948","article-title":"Phase I studies of the safety, tolerability, pharmacokinetics and pharmacodynamics of the dual glucagon receptor\/glucagon-like peptide-1 receptor agonist BI 456906","volume":"25","author":"Jungnik","year":"2023","journal-title":"Diabetes Obes. Metab."},{"issue":"2","key":"10.1016\/j.biopha.2024.116888_bib69","doi-asserted-by":"crossref","first-page":"235","DOI":"10.2337\/db16-0994","article-title":"Glucagon and amino acids are linked in a mutual feedback cycle: the liver-alpha-cell axis","volume":"66","author":"Holst","year":"2017","journal-title":"Diabetes"},{"key":"10.1016\/j.biopha.2024.116888_bib70","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2020.101080","article-title":"Glucagon acutely regulates hepatic amino acid catabolism and the effect may be disturbed by steatosis","volume":"42","author":"Winther-Sorensen","year":"2020","journal-title":"Mol. Metab."},{"issue":"7","key":"10.1016\/j.biopha.2024.116888_bib71","doi-asserted-by":"crossref","first-page":"405","DOI":"10.3390\/nu8070405","article-title":"The emerging role of branched-chain amino acids in insulin resistance and metabolism","volume":"8","author":"Yoon","year":"2016","journal-title":"Nutrients"},{"key":"10.1016\/j.biopha.2024.116888_bib72","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/2794591","article-title":"The relationship between branched-chain amino acid related metabolomic signature and insulin resistance: a systematic review","volume":"2016","author":"Zhao","year":"2016","journal-title":"J. Diabetes Res."},{"issue":"10","key":"10.1016\/j.biopha.2024.116888_bib73","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0186586","article-title":"Glucagon like receptor 1\/ glucagon dual agonist acutely enhanced hepatic lipid clearance and suppressed de novo lipogenesis in mice","volume":"12","author":"More","year":"2017","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.biopha.2024.116888_bib74","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.93626","article-title":"Peroxisomal beta-oxidation regulates whole body metabolism, inflammatory vigor, and pathogenesis of nonalcoholic fatty liver disease","volume":"3","author":"Moreno-Fernandez","year":"2018","journal-title":"JCI Insight"}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332224007728?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332224007728?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T23:13:01Z","timestamp":1781651581000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332224007728"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":74,"alternative-id":["S0753332224007728"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2024.116888","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chronic treatment with glucagon-like peptide-1 and glucagon receptor co-agonist causes weight loss-independent improvements in hepatic steatosis in mice with diet-induced obesity","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2024.116888","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"116888"}}